Abba Medix Corp. Introduces Three Additional Strains for Sale

Published: January 23, 2020

Abba Medix Corp. Introduces Three Additional Strains for Sale

Canada House Wellness Group Inc. announced that its wholly owned subsidiary, Abba Medix Corp. (“Abba“), has introduced three additional strains to its product portfolio: Sage & Sour, Critical Orange Punch, and White Shark.  The new strains will be available for sale on Monday January 27, 2020 to registered Abba patients at www.abbamedix.com.  Profiles of each additional strain can also be found under the “Products” tab on Abba’s website.

Abba produces handcrafted, premium quality, medical grade cannabis for patients seeking safe solutions for their complex to common health and wellness needs.  Abba now has a total of four strains available for sale to registered Abba patients.  Abba expects to have additional derivative products, including oils, coming online this calendar year.

“Adding these 3 strains to Abba’s menu is an important milestone for our organization.  We are committed to having high quality strains on our menu to best serve our medical patients looking for solutions to a variety of health and wellness needs.  As Abba’s patient base continues to grow, we will strategically and selectively add complementary strains that our patients covet,” said Michael Orrbrooke, Abba’s President and the Chief Revenue Officer of Canada House.  “In addition to offering a more comprehensive selection of strains, we intend to offer our products in new formats to provide our medical patients with many options while maintaining our industry leading customer service and online customer experience.”

“A key strategy of Canada House is to increase Abba’s patient base through relationships with clinics across Canada,” says Canada House CEO Chris Churchill-Smith.  “We have listened to our patients and have increased the selection of cannabis products to meet their needs.  This is yet another significant milestone for Canada House on our Path to Profitability, as it will ensure that our growing base of high-value medical patients have a selection of options when ordering medical cannabis from Abba.”

The Company also announced the issuance of 1,280,683 common shares at a deemed price per share of $0.04685 for strategic financial advisory services rendered pursuant to an engagement letter with a nationally recognized financial advisory firm and 333,333 common shares at a deemed price per share of $0.03 for human resource services rendered pursuant to a consulting agreement with an independent third-party.

Recent News

View All News Items

Latest Article

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

The legalization of cannabis edibles, extracts and topicals will expand the cannabis market and create new opportunities for producers, innovators and investors. According to a recent report from Deloitte, the Canadian market for these new cannabis products is expected to be worth $2.7 billion annually, with edibles accounting for more than half ($1.6 billion).

 

Read Article